稳定性冠脉支架患者非心脏手术围术期阿司匹林单药与停用抗血小板治疗的随机对照研究
ASSURE-DES 随机对照试验纳入 1010 例既往置入药物洗脱支架超过 1 年、拟行择期低至中危非心脏手术的患者,比较继续阿司匹林单药与术前 5 天停用全部抗血小板治疗。改良意向性治疗人群 926 例中,主要复合终点(死亡、心肌梗死、支架血栓或卒中)发生率分别为 0.6% 与 0.9%,差异无统计学意义,两组均无支架血栓,大出血无显著差异,但阿司匹林组小出血更常见。
要点
- 支架置入超过 1 年的低至中危非心脏手术患者,围术期继续阿司匹林单药与停用抗血小板治疗的缺血事件无显著差异。
- 两组支架血栓均为零,大出血发生率无显著差异,但阿司匹林组小出血显著增多。
- 研究事件率低于预期,结论需结合个体缺血与出血风险审慎解读。
核心结论
- 在支架置入超过 1 年、以药物洗脱支架为主的患者行低至中危非心脏手术时,围术期阿司匹林单药与停用全部抗血小板治疗在缺血结局或大出血方面未见显著差异。
研究设计与样本
- 多中心随机对照试验 ASSURE-DES(NCT02797548),共随机分配 1010 例既往置入药物洗脱支架超过 1 年、拟行择期非心脏手术的患者。
- 干预为继续阿司匹林单药 versus 术前 5 天停用全部抗血小板药物,建议术后不超过 48 小时恢复抗血小板治疗(除非禁忌)。
- 改良意向性治疗人群 926 例,其中阿司匹林单药组 462 例、无抗血小板治疗组 464 例。
主要发现
- 主要复合终点(全因死亡、心肌梗死、支架血栓或卒中,术前 5 天至术后 30 天)在阿司匹林组发生 3 例(0.6%),无抗血小板组发生 4 例(0.9%),差异 -0.2 个百分点(95%CI:-1.3 至 0.9;P > 0.99)。
- 两组均未发生支架血栓。
- 大出血发生率两组无显著差异(6.5% vs 5.2%;P = 0.39)。
- 小出血在阿司匹林组显著更常见(14.9% vs 10.1%;P = 0.027)。
临床怎么用
- 对于支架置入超过 1 年、拟行低至中危非心脏手术的患者,围术期继续阿司匹林单药或术前停用抗血小板治疗均为可选策略,需权衡缺血与出血风险。
- 阿司匹林组小出血更多,临床决策时应关注小出血风险。
局限性
- 研究事件率低于预期,可能削弱检验效能,无法排除小差异。
- 研究对象以药物洗脱支架为主且支架置入超过 1 年,结论不宜外推至支架置入时间较短或高危手术患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines recommend the perioperative continuation of aspirin in patients with coronary drug-eluting stents (DES) undergoing noncardiac surgery. However, supporting evidence is limited. OBJECTIVES: This study aimed to compare continuing aspirin monotherapy vs temporarily holding all antiplatelet therapy before noncardiac surgery in patients with previous DES implantation. METHODS: We randomly assigned patients who had received a DES >1 year previously and were undergoing elective noncardiac surgery either to continue aspirin or to discontinue all antiplatelet agents 5 days before noncardiac surgery. Antiplatelet therapy was recommended to be resumed no later than 48 hours after surgery, unless contraindicated. The primary outcome was a composite of death from any cause, myocardial infarction, stent thrombosis, or stroke between 5 days before and 30 days after noncardiac surgery. RESULTS: A total of 1,010 patients underwent randomization. Among 926 patients in the modified intention-to-treat population (462 patients in aspirin monotherapy group and 464 patients in the no-antiplatelet therapy group), the primary composite outcome occurred in 3 patients (0.6%) in the aspirin monotherapy group and 4 patients (0.9%) in the no antiplatelet group (difference, -0.2 percentage points; 95% CI: -1.3 to 0.9; P > 0.99). There was no stent thrombosis in either group. The incidence of major bleeding did not differ significantly between groups (6.5% vs 5.2%; P = 0.39), whereas minor bleeding was significantly more frequent in the aspirin group (14.9% vs 10.1%; P = 0.027). CONCLUSIONS: Among patients undergoing low-to-intermediate risk noncardiac surgery >1 year after stent implantation primarily with a DES, in the setting of lower-than-expected event rates, we failed to identify a significant difference between perioperative aspirin monotherapy and no antiplatelet therapy with respect to ischemic outcomes or major bleeding. (Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery [ASSURE-DES]; NCT02797548).
引用
- Kang DY, Lee SH, Lee SW, et al. Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery. J Am Coll Cardiol. 2024. PMID: 39217573. doi:10.1016/j.jacc.2024.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。